MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 300.38 Thousand CAD | -1.2% |
| 2022 | 304.02 Thousand CAD | -82.34% |
| 2021 | 1.72 Million CAD | 200.86% |
| 2020 | 572.28 Thousand CAD | 35.18% |
| 2019 | 423.35 Thousand CAD | -8.19% |
| 2018 | 461.11 Thousand CAD | -3.59% |
| 2017 | 478.29 Thousand CAD | -53.08% |
| 2016 | 1.01 Million CAD | -13.65% |
| 2015 | 1.18 Million CAD | 52.35% |
| 2014 | 774.79 Thousand CAD | 22.83% |
| 2013 | 630.77 Thousand CAD | 6.15% |
| 2012 | 594.23 Thousand CAD | 42.86% |
| 2011 | 415.95 Thousand CAD | -43.41% |
| 2010 | 735.02 Thousand CAD | 31.86% |
| 2009 | 557.4 Thousand CAD | 3.57% |
| 2008 | 538.21 Thousand CAD | -32.64% |
| 2007 | 798.99 Thousand CAD | -30.0% |
| 2006 | 1.14 Million CAD | 5.07% |
| 2005 | 1.08 Million CAD | -15.49% |
| 2004 | 1.28 Million CAD | 201.26% |
| 2003 | 426.65 Thousand CAD | 227.96% |
| 2002 | -333.43 Thousand CAD | -1160.65% |
| 2001 | 31.43 Thousand CAD | -37.25% |
| 2000 | 50.1 Thousand CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -195.11 Thousand CAD | 3.44% |
| 2024 Q2 | -149.95 Thousand CAD | -312.3% |
| 2024 Q1 | 70.63 Thousand CAD | 38.71% |
| 2023 Q1 | 98.26 Thousand CAD | 1.15% |
| 2023 FY | 300.38 Thousand CAD | -1.2% |
| 2023 Q2 | 89.93 Thousand CAD | -8.48% |
| 2023 Q3 | 61.25 Thousand CAD | -31.89% |
| 2023 Q4 | 50.92 Thousand CAD | -16.87% |
| 2022 Q4 | 97.14 Thousand CAD | 0.57% |
| 2022 Q3 | 96.59 Thousand CAD | 12.86% |
| 2022 FY | 304.02 Thousand CAD | -82.34% |
| 2022 Q1 | 24.69 Thousand CAD | -71.12% |
| 2022 Q2 | 85.59 Thousand CAD | 246.62% |
| 2021 Q3 | 35.83 Thousand CAD | -84.95% |
| 2021 Q1 | 1.36 Million CAD | 288.07% |
| 2021 Q2 | 238.13 Thousand CAD | -82.52% |
| 2021 FY | 1.72 Million CAD | 200.86% |
| 2021 Q4 | 85.49 Thousand CAD | 138.57% |
| 2020 Q1 | 71.68 Thousand CAD | -14.73% |
| 2020 Q3 | 70.34 Thousand CAD | -11.2% |
| 2020 Q2 | 79.21 Thousand CAD | 10.5% |
| 2020 FY | 572.28 Thousand CAD | 35.18% |
| 2020 Q4 | 351.03 Thousand CAD | 399.03% |
| 2019 FY | 423.35 Thousand CAD | -8.19% |
| 2019 Q1 | 114.98 Thousand CAD | -21.74% |
| 2019 Q2 | 104.41 Thousand CAD | -9.19% |
| 2019 Q3 | 119.89 Thousand CAD | 14.83% |
| 2019 Q4 | 84.06 Thousand CAD | -29.88% |
| 2018 Q1 | 112.6 Thousand CAD | 3.63% |
| 2018 FY | 461.11 Thousand CAD | -3.59% |
| 2018 Q4 | 146.93 Thousand CAD | 145.99% |
| 2018 Q3 | 59.72 Thousand CAD | -57.89% |
| 2018 Q2 | 141.84 Thousand CAD | 25.97% |
| 2017 Q2 | 133.65 Thousand CAD | 11.75% |
| 2017 FY | 478.29 Thousand CAD | -53.08% |
| 2017 Q4 | 108.66 Thousand CAD | -6.63% |
| 2017 Q3 | 116.38 Thousand CAD | -12.92% |
| 2017 Q1 | 119.6 Thousand CAD | 255.31% |
| 2016 Q1 | 585.78 Thousand CAD | 34.46% |
| 2016 FY | 1.01 Million CAD | -13.65% |
| 2016 Q2 | 236.02 Thousand CAD | -59.71% |
| 2016 Q3 | 163.82 Thousand CAD | -30.59% |
| 2016 Q4 | 33.66 Thousand CAD | -79.45% |
| 2015 Q4 | 435.64 Thousand CAD | 88.42% |
| 2015 Q3 | 231.21 Thousand CAD | -27.67% |
| 2015 FY | 1.18 Million CAD | 52.35% |
| 2015 Q2 | 319.66 Thousand CAD | 64.9% |
| 2015 Q1 | 193.85 Thousand CAD | -12.41% |
| 2014 Q4 | 221.31 Thousand CAD | 5.14% |
| 2014 FY | 774.79 Thousand CAD | 22.83% |
| 2014 Q3 | 210.48 Thousand CAD | 3.91% |
| 2014 Q1 | 140.43 Thousand CAD | -44.74% |
| 2014 Q2 | 202.56 Thousand CAD | 44.24% |
| 2013 Q4 | 254.13 Thousand CAD | 410.45% |
| 2013 Q2 | 159.81 Thousand CAD | -4.32% |
| 2013 Q1 | 167.03 Thousand CAD | 58.47% |
| 2013 Q3 | 49.78 Thousand CAD | -68.85% |
| 2013 FY | 630.77 Thousand CAD | 6.15% |
| 2012 FY | 594.23 Thousand CAD | 42.86% |
| 2012 Q1 | 146.47 Thousand CAD | 56.29% |
| 2012 Q2 | 173.58 Thousand CAD | 18.5% |
| 2012 Q4 | 105.4 Thousand CAD | -19.78% |
| 2012 Q3 | 131.39 Thousand CAD | -24.31% |
| 2011 Q4 | 93.72 Thousand CAD | -36.95% |
| 2011 FY | 415.95 Thousand CAD | -43.41% |
| 2011 Q2 | 87.81 Thousand CAD | 2.38% |
| 2011 Q1 | 85.77 Thousand CAD | 132.83% |
| 2011 Q3 | 148.65 Thousand CAD | 69.28% |
| 2010 FY | 735.02 Thousand CAD | 31.86% |
| 2010 Q4 | -261.23 Thousand CAD | -158.41% |
| 2010 Q3 | 447.25 Thousand CAD | 34.89% |
| 2010 Q2 | 331.55 Thousand CAD | 52.48% |
| 2010 Q1 | 217.44 Thousand CAD | 2467.58% |
| 2009 Q3 | 197.49 Thousand CAD | 74.88% |
| 2009 Q2 | 112.93 Thousand CAD | -52.65% |
| 2009 Q1 | 238.51 Thousand CAD | 674.57% |
| 2009 FY | 557.4 Thousand CAD | 3.57% |
| 2009 Q4 | 8469.00 CAD | -95.71% |
| 2008 Q1 | 60 Thousand CAD | 193.03% |
| 2008 FY | 538.21 Thousand CAD | -32.64% |
| 2008 Q4 | 30.79 Thousand CAD | -64.45% |
| 2008 Q3 | 86.61 Thousand CAD | -75.55% |
| 2008 Q2 | 354.18 Thousand CAD | 490.31% |
| 2007 Q4 | -64.49 Thousand CAD | -127.21% |
| 2007 Q2 | 344.66 Thousand CAD | 22.3% |
| 2007 FY | 798.99 Thousand CAD | -30.0% |
| 2007 Q3 | 237.01 Thousand CAD | -31.23% |
| 2007 Q1 | 281.81 Thousand CAD | 9.17% |
| 2006 Q3 | 35.51 Thousand CAD | -94.46% |
| 2006 Q4 | 258.14 Thousand CAD | 626.83% |
| 2006 FY | 1.14 Million CAD | 5.07% |
| 2006 Q1 | 206.02 Thousand CAD | 463.04% |
| 2006 Q2 | 641.65 Thousand CAD | 211.44% |
| 2005 Q1 | 387.44 Thousand CAD | 13.6% |
| 2005 Q2 | 403.13 Thousand CAD | 4.05% |
| 2005 Q3 | 259.07 Thousand CAD | -35.73% |
| 2005 Q4 | 36.59 Thousand CAD | -85.88% |
| 2005 FY | 1.08 Million CAD | -15.49% |
| 2004 Q2 | 268.89 Thousand CAD | -20.05% |
| 2004 Q4 | 341.05 Thousand CAD | 0.59% |
| 2004 FY | 1.28 Million CAD | 201.26% |
| 2004 Q1 | 336.33 Thousand CAD | -44.9% |
| 2004 Q3 | 339.06 Thousand CAD | 26.09% |
| 2003 Q2 | 15.18 Thousand CAD | 23.29% |
| 2003 Q4 | 610.43 Thousand CAD | 389.86% |
| 2003 Q3 | -210.59 Thousand CAD | -1487.06% |
| 2003 FY | 426.65 Thousand CAD | 227.96% |
| 2003 Q1 | 12.31 Thousand CAD | 103.37% |
| 2002 Q2 | 5906.00 CAD | 116.92% |
| 2002 Q1 | -34.91 Thousand CAD | 0.0% |
| 2002 FY | -333.43 Thousand CAD | -1160.65% |
| 2002 Q3 | 60.56 Thousand CAD | 925.45% |
| 2002 Q4 | -364.99 Thousand CAD | -702.67% |
| 2001 FY | 31.43 Thousand CAD | -37.25% |
| 2000 FY | 50.1 Thousand CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 3725.613% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 97.997% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 96.933% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -357.008% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 97.434% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.748% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 979.596% |
| Marizyme, Inc. | 457.7 Thousand USD | 34.372% |
| Genus plc | 178.7 Million USD | 99.832% |
| Pharming Group N.V. | 220.1 Million USD | 99.864% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -382.727% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 26.766% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 2830.745% |
| ContraFect Corporation | -154 Thousand USD | 295.053% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -291.321% |
| IMV Inc. | -962.29 Thousand USD | 131.215% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 177.518% |
| ONE Bio Corp. | 20.12 Million USD | 98.507% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.254% |
| Mesoblast Limited | -35.16 Million USD | 100.854% |
| MultiCell Technologies, Inc. | 49.32 USD | -608947.04% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.937% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.927% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -9583.495% |
| Biomind Labs Inc. | -15.42 Thousand USD | 2047.497% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 126.313% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -329.117% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 341.754% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 6165.872% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 700.764% |
| Arch Therapeutics, Inc. | -2439.00 USD | 12415.785% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -113.795% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -514.278% |
| Q BioMed Inc. | -8988.00 USD | 3442.034% |
| GB Sciences, Inc. | -624.00 USD | 48238.141% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 449.168% |
| CSL Limited | 7.56 Billion USD | 99.996% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.323% |
| Enzolytics Inc. | 30.7 Thousand USD | -878.188% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 37.736% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 408.037% |
| argenx SE | 1.1 Billion USD | 99.973% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.164% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 144514.423% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 158.382% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 3491.847% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 51.346% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 458.242% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 69.596% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 96.875% |
| Kadimastem Ltd | -630.13 Thousand USD | 147.669% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 98.053% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 2638.082% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 722.437% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -70.13% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -70.13% |
| Affymax, Inc. | 1.35 Million USD | 77.867% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 93.481% |
| CytoDyn Inc. | -29 Thousand USD | 1135.8% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 33.255% |
| SYBLEU INC | 11.69 Thousand USD | -2468.246% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 194.014% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 180.531% |
| Neutra Corp. | 14.33 Thousand USD | -1995.445% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 466.32% |
| PureTech Health plc | -1.6 Million USD | 118.739% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 130.001% |
| IXICO plc | 3.27 Million USD | 90.814% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 143.283% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 116.772% |
| CSL Limited | 7.7 Billion USD | 99.996% |
| Cellectis S.A. | 18 Thousand USD | -1568.789% |